Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/4/2020
SIETES contiene 92957 citas

 
 
 1 a 20 de 427 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Dimmitt SB, Stampfer HG. Polypill for prevention of cardiovascular diseases. Lancet 2020;395:413-4. [Ref.ID 103520]
2.Tiene citas relacionadas Cita con resumen
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019;394:24 de agosto. [Ref.ID 103246]
3.Enlace a cita original Cita con resumen
Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, Thurin N, Droz-Perroteau C, Gulmez SE. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French National Healthcare Data System. Drug Saf 2019;42:abril. [Ref.ID 103083]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
5.Enlace a cita original Cita con resumen
Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:abril. [Ref.ID 102565]
6. Cita con resumen
Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]
7. Cita con resumen
Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, See L-C, Kuo C-F. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017;318:1250-9. [Ref.ID 102073]
8. Cita con resumen
Pedro-Botet J, Rubiés-Prat J. Statin-associated muscle symptoms: beware of the nocebo effect. Lancet 2017;389:2445-6. [Ref.ID 101655]
10. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
11. Cita con resumen
Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiology 2016:9 de noviembre. [Ref.ID 100967]
12. Cita con resumen
Anónimo. Lipid-lowering drugs. Med Lett Drugs Ther 2016;58:133-40. [Ref.ID 100944]
13. Cita con resumen
Anónimo. Alirocumab. Prescrire 2016;36:331-2. [Ref.ID 100534]
14. Cita con resumen
Anónimo. Évolocumab. Prescrire 2016;36:326-31. [Ref.ID 100533]
15. Cita con resumen
Zhang F, Mamtani R, Scott FI, Goldberg DS, Haynes K, Lewis JD. Increasing use of prescription drugs in the United Kingdom. Pharmacoepidemiol Drug Saf 2016;25:628-36. [Ref.ID 100019]
16. Cita con resumen
Ezquerra Pérez G, Martín de la Nava MA, Álvarez-Cienfuegos A, Montaño Barrientos A, Baquero Barroso MJ, Rubio Núñez PL, Gómez Santana MC, Gavilán Moral E, Candela Marroquín E, Sánchez Robles GA. Revisión GRADE de estatinas en población con = 90% en prevención primaria cardiovascular. Sección 3: Efectos adversos. II. Miopatías.. Grupo Evalmed-GRADE 2016:21 de enero. [Ref.ID 99983]
17. Cita con resumen
Kmietowicz Z. Pfizer and Allergan agree $160bn merger deal. BMJ 2015;351:h6342. [Ref.ID 99704]
18. Cita con resumen
Cederberg H, Stancáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia 2015;58:1109-17. [Ref.ID 99019]
19. Cita con resumen
Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, Rahme E, Tamim H, Lipscombe L, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014;348:g3244. [Ref.ID 98059]
20. Cita con resumen
Anónimo. Pfizer faces mounting number of lawsuits over lipitor side effects. DIA Daily 2014:11 de agosto. [Ref.ID 98015]
Seleccionar todas
 
 1 a 20 de 427 siguiente >>